MedTrace Logo

Topical Naloxone to Diagnose Ocular Pain

NCT04454281 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-11-08

No results posted yet for this study

Summary

Chronic ocular neuropathic pain may be misdiagnosed as dry eye disease. Our study aims to identify a population with previous monocular trauma and dry eye symptoms and differentiate neuropathic from dry eye pain using topical corneal naloxone hydrochloride.

Conditions

  • Dry Eye Syndromes
  • Neuropathic Pain

Interventions

DRUG

Naloxone Hydrochloride 0.4 MG/ML

Drug will be topically applied to the corneal surface then study evaluations will ensue.

Sponsors & Collaborators

  • Seema Capoor

    lead OTHER

Principal Investigators

  • Seema Capoor, MD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2020-12-03
Completion
2020-12-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04454281 on ClinicalTrials.gov